Tatsuya Fujii
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tatsuya Fujii has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Yoshiaki Kitamura
Department of Otolaryngology, Graduate School of Medicine, Tokushima University, Tokushima, Japan
3 shared publications - Seiichiro Kamimura
Department of Otolaryngology-Head and Neck Surgery, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770-8503, Japan
2 shared publications Akira Fujioka
C Nichia Corporation , Tokushima , Japan
1 shared publication- Atsushi Nagai
Department of Neurology, Faculty of Medicine, Shimane University, 89-1 Enya Cho, Izumo 693-8501, Japan
1 shared publication - Eiji Kondo
Tokushima University Graduate School, Institute of Biomedical Sciences, Department of Otolaryngology-Head and Neck Surgery, Tokushima, Japan
1 shared publication - Go Sato
Department of Otolaryngology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
1 shared publication
Latest Publications
- Open Access
- 18 November 2025
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 10 (6)
High Remission Rate in Eosinophilic Chronic Rhinosinusitis Following More Than Two Years of Dupilumab Therapy
Objective: This study aimed to evaluate the clinical remission rate and changes in medication use in patients with eosinophilic chronic rhinosinusitis (ECRS) treated with dupilumab for > 2 years. Methods: This retrospective study included 19 patients with ECRS who received dupilumab therapy for > 2 years. The nasal polyp, Lund–Mackay on sinus CT, and SNOT‐22 scores were assessed at baseline, 3 months, 1 year, and at the final evaluation. Remission was defined as sustained fulfillment of specific clinical and endoscopic criteria for at least 12 months. The use of concomitant medications was also assessed. Results: Polyp score significantly improved from 6.1 ± 0.6 at baseline to 0.68 ± 1.2 at final evaluation. SNOT‐22 scores decreased from 42.8 ± 20.0 to 14.1 ± 10.2. Clinical remission was achieved in 15 patients (79%). The remaining four patients did not meet the remission criteria because of persistent olfactory dysfunction or nasal obstruction. Significant reductions in the use of oral corticosteroids, drop‐type intranasal corticosteroids, nasal spray corticosteroids, leukotriene receptor antagonists, and inhaled corticosteroids were also observed. Conclusion: Dupilumab therapy for > 2 years resulted in a high clinical remission rate and reduced the need for concomitant medications in patients with ECRS. Persistent olfactory dysfunction is the main reason for non‐remission, indicating the need for further therapeutic strategies in such refractory cases. Level of Evidence: 3.
- 18 November 2025
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 10 (6)
Open AccessHigh Remission Rate in Eosinophilic Chronic Rhinosinusitis Following More Than Two Years of Dupilumab Therapy
Objective: This study aimed to evaluate the clinical remission rate and changes in medication use in patients with eosinophilic chronic rhinosinusitis (ECRS) treated with dupilumab for > 2 years. Methods: This retrospective study included 19 patients with ECRS who received dupilumab therapy for > 2 years. The nasal polyp, Lund–Mackay on sinus CT, and SNOT‐22 scores were assessed at baseline, 3 months, 1 year, and at the final evaluation. Remission was defined as sustained fulfillment of specific clinical and endoscopic criteria for at least 12 months. The use of concomitant medications was also assessed. Results: Polyp score significantly improved from 6.1 ± 0.6 at baseline to 0.68 ± 1.2 at final evaluation. SNOT‐22 scores decreased from 42.8 ± 20.0 to 14.1 ± 10.2. Clinical remission was achieved in 15 patients (79%). The remaining four patients did not meet the remission criteria because of persistent olfactory dysfunction or nasal obstruction. Significant reductions in the use of oral corticosteroids, drop‐type intranasal corticosteroids, nasal spray corticosteroids, leukotriene receptor antagonists, and inhaled corticosteroids were also observed. Conclusion: Dupilumab therapy for > 2 years resulted in a high clinical remission rate and reduced the need for concomitant medications in patients with ECRS. Persistent olfactory dysfunction is the main reason for non‐remission, indicating the need for further therapeutic strategies in such refractory cases. Level of Evidence: 3.
- 4 January 2022
- Published by Elsevier in Auris Nasus Larynx
- Vol. 49 (4) , 697-702
Long-term changes in serum squamous cell carcinoma antigen levels after surgery in patients with sinonasal inverted papilloma
- 4 January 2022
- Published by Elsevier in Auris Nasus Larynx
- Vol. 49 (4) , 697-702
Long-term changes in serum squamous cell carcinoma antigen levels after surgery in patients with sinonasal inverted papilloma
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e228-e229
Therapeutic effect of indoleamine 2,3-dioxygenase inhibitor in epididymitis
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e228-e229
Therapeutic effect of indoleamine 2,3-dioxygenase inhibitor in epididymitis
- 29 January 2016
- Published by Taylor & Francis in Acta Oto-Laryngologica
- Vol. 136 (4) , 409-413
Irradiation with narrowband-ultraviolet B suppresses phorbol ester-induced up-regulation of H1receptor mRNA in HeLa cells
Conclusion These findings suggest that low dose irradiation with 310 nm NB-UVB specifically suppressed the up-regulation of H1R gene expression without inducing apoptosis and that UVB of shorter or longer wavelength than 310 nm NB-UVB had no such effects. Objective To develop a narrowband-ultraviolet B(NB-UVB) phototherapy for allergic rhinitis, this study investigated the effects of irradiation with NB-UVB at wavelength of 310 nm on phorbol-12-myristate-13-acetate (PMA)-induced up-regulation of histamine H1 receptor (H1R) mRNA in HeLa cells. Methods The mRNA levels of H1R in HeLa cells were measured using real-time RT-PCR. Apoptosis were evaluated with DNA fragmentation assay. Results PMA induced a significant increase in H1R mRNA expression in HeLa cells. Irradiation with 305 nm UVB and 310 nm NB-UVB, but not with 315 nm UVB at doses of 200 and 300 mJ/cm2 significantly suppressed PMA-induced up-regulation of H1R mRNA. At a dose of 200 mJ/cm2, irradiation with 305 nm UVB, but not with 310 nm NB-UVB, induced apoptosis, although exposure of the cells to both 305 and 310 nm UVB induced apoptosis at a dose of 300 mJ/cm2 after PMA treatment in HeLa cells. Conversely, irradiation with 315 nm UVB at doses of 200 and 300 mJ/cm2 did not induce apoptosis.
- 29 January 2016
- Published by Taylor & Francis in Acta Oto-Laryngologica
- Vol. 136 (4) , 409-413
Irradiation with narrowband-ultraviolet B suppresses phorbol ester-induced up-regulation of H1receptor mRNA in HeLa cells
Conclusion These findings suggest that low dose irradiation with 310 nm NB-UVB specifically suppressed the up-regulation of H1R gene expression without inducing apoptosis and that UVB of shorter or longer wavelength than 310 nm NB-UVB had no such effects. Objective To develop a narrowband-ultraviolet B(NB-UVB) phototherapy for allergic rhinitis, this study investigated the effects of irradiation with NB-UVB at wavelength of 310 nm on phorbol-12-myristate-13-acetate (PMA)-induced up-regulation of histamine H1 receptor (H1R) mRNA in HeLa cells. Methods The mRNA levels of H1R in HeLa cells were measured using real-time RT-PCR. Apoptosis were evaluated with DNA fragmentation assay. Results PMA induced a significant increase in H1R mRNA expression in HeLa cells. Irradiation with 305 nm UVB and 310 nm NB-UVB, but not with 315 nm UVB at doses of 200 and 300 mJ/cm2 significantly suppressed PMA-induced up-regulation of H1R mRNA. At a dose of 200 mJ/cm2, irradiation with 305 nm UVB, but not with 310 nm NB-UVB, induced apoptosis, although exposure of the cells to both 305 and 310 nm UVB induced apoptosis at a dose of 300 mJ/cm2 after PMA treatment in HeLa cells. Conversely, irradiation with 315 nm UVB at doses of 200 and 300 mJ/cm2 did not induce apoptosis.